Navigation Links
Plicera in Medical Technology

Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease

Phase 2 Clinical Trials Initiated CRANBURY, N.J., March 21, 2007 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, announced today that it will present p...

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

...olly-owned subsidiary of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, plicera and AT2220. Under the terms of the collaboration Shire will pay development and sales milestones up to a maximum of $390 million, and will also pay ti...

Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent

...trengthens our protection in the United States for plicera in Gaucher and is one example of our ongoing effor...armacological chaperone technology platform." plicera is currently being studied in an ongoing Phase 2 s...e third quarter of 2009. Amicus is developing plicera as part of a strategic collaboration with Shire Hu...

Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease

... medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. Forward-Looking Statements This press release contain...

Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009

...he dose and regimen for the Phase 3 studies. plicera (TM) (isofagomine tartrate) for the treatment of Gaucher Disease A Phase 2 clinical trial of plicera in Gaucher patients is ongoing. This 6 month study...er Shire HGT to prepare for Phase 3 development of plicera pending the results of the ongoing Phase 2 trial. ...

Amicus Therapeutics Announces Second Quarter 2008 Financial Results

... for the ongoing 6-month Phase 2 clinical trial of plicera in patients naive to ERT to include modified doses... The Company has modified its development plan for plicera to include a study of the pharmacokinetics of plicera in Gaucher patients. In addition, the company no l...

Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease

...Nashville, TN. The data demonstrate the ability of plicera to increase levels of the target enzyme in cells d...l data from both studies will also be presented. plicera is designed to selectively bind to and stabilize G... The following is a summary of the preclinical plicera data being presented at ACMG. - In vitro ex...
Plicera in Biological Technology

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

...rldwide will participate in this trial. plicera (TM) (afegostat tartrate) for the treatment of ...inical trial of the Company's investigational drug plicera is ongoing. This 6-month study is designed to eval..., Shire HGT, to prepare for Phase 3 development of plicera pending the results of the ongoing Phase 2 trial. ...

Publication of Shire plc's Annual Report 2008

...IGAL and AT2220, in markets outside the US. plicera (HGT-3410 for the treatment of Gaucher disease) plicera is an orally-administered, small molecule pharmaco...port the previously reported interim findings that plicera was generally safe and well tolerated at all doses...

Amicus Therapeutics Announces Change to Board of Directors

... medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. FOLD-G ...

Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results

... be available in the first quarter of 2009. plicera (TM) (isofagomine tartrate) for the treatment o...on executing its ongoing Phase 2 clinical trial of plicera in Gaucher disease. This 6-month study is designed..., Shire HGT, to prepare for Phase 3 development of plicera pending the results of the ongoing Phase 2 trial. ...

Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date

... medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. FOLD -G ...

Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors

...medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. FOLD-G ...

Amicus Therapeutics Announces Third Quarter 2008 Financial Results

...ucher disease. As previously disclosed, a 6-month Phase 2 clinical trial of plicera in patients naive to ERT is ongoing and Amicus expects the results of this ...harmacological chaperone compounds for lysosomal storage disorders, Amigal, plicera and AT2220. In this collaboration, valued at up to $440 million including a...

Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.

...s Phase 2 trial support the previously reported interim findings that plicera was generally safe and well tolerated at all doses and increased target enzyme activity levels in a majority of patients. Shire has rights to plicera in markets outside the US. HGT-3510 - Pompe disease - In June 2008 Ami...

Amicus Therapeutics Announces First Quarter 2008 Financial Results

...macological chaperone Plicera. Results showed that plicera was generally safe and well tolerated at all doses...protocol for the 6-month Phase 2 clinical trial of plicera patients naive to ERT to include modified doses an...compounds for lysosomal storage disorders, Amigal, plicera and AT2220. In this collaboration valued at up to ...

Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance

...ine) METAZYM(TM) (arylsulfatase-A) MEZAVANT(R) (mesalazine) PENTASA (mesalamine) (trademark of Ferring) plicera (isofagomine tartrate) (trademark of Amicus) RAZADYNE (galantamine) (trademark of Johnson & Johnson ...
Other Tags
(Date:4/17/2015)... At the end of February 2015, Choices ... to the Oscars” in the Stardust Penthouse on the ... impressive Los Angeles skyline. These events honoring the 2015 ... leading producer of sustainable product placement in TV and ... providers of eco-friendly and socially conscious products and services, ...
(Date:4/17/2015)... Organic Valley, the nation’s largest cooperative of ... Year of Soils by “Cycling for Sustainability” through California ... will travel 215 miles from Auburn, California, to the ... the impact of agriculture on water and soil in ... Wisconsin, Oregon, and Washington state, the cyclists have diverse ...
(Date:4/17/2015)... Calvary Hospital recently announced Timothy P. Barr ... President on May 11. The Fund directs all fundraising efforts ... succeeds Vincent J. Spinelli, who retired several months ago. , ... and supervise the important work that the Fund does every ... continues to expand and bring our signature care to people ...
(Date:4/17/2015)... Lowcostcarinsuranceprice.com has released a new blog post explaining the ... car insurance rates . , Falling asleep at ... have a big impact on auto insurance prices. The premiums ... claimed benefits. The newly released blog post talks more about ... , It is now possible to find low cost ...
(Date:4/17/2015)... Wholelifelifeinsurance.org has released a new blog post ... policies . , Whole life insurance can help ... families at the same time. Whole life insurance is ... customized to it the client’s needs. , Whole ... some appropriate steps.Comparing life insurance quotes is very important ...
Breaking Medicine News(10 mins):Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2Health News:Organic Valley Farmers and Employees "Cycling for Sustainability" Through 215 Miles of California Watershed April 19-25 2Health News:Organic Valley Farmers and Employees "Cycling for Sustainability" Through 215 Miles of California Watershed April 19-25 3Health News:Timothy P. Barr Appointed Executive Vice President of Calvary Fund 2Health News:Timothy P. Barr Appointed Executive Vice President of Calvary Fund 3Health News:Accidents Caused By Sleeping at The Wheel Can Increase Auto Insurance Costs 2Health News:Whole Life Insurance Policies At Affordable Prices By Comparing Quotes 2
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... Wocket smart wallets is underway to early access pre-order ... group includes usage at retail outlets including Walmart, Target, ... Users report Wocket was accepted at all outlets and ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
Other Contents